The prognosis of acute promyelocytic leukemia (APL) has greatly improved with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), but early death (ED) remains a major treatment failure cause, accounting for 20%-25% of fatalities within the first 30 days. 1